TG Therapeutics, Inc. (NASDAQ:TGTX) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k

8 years ago

TG Therapeutics, Inc. (NASDAQ:TGTX) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07.Submission of Matters to a Vote of Security Holders.

TG Therapeutics, Inc. (the Company) held its annual meeting of
stockholders on Friday, June 16, 2017 at the offices of its legal
counsel, Alston Bird LLP, 90 Park Avenue, New York, New York
10016 at 9:30 a.m. Eastern Standard Time. Stockholders
representing 44,891,432, or 67.19%, of the 66,816,455 shares
entitled to vote were present in person or by proxy. Proxies were
solicited by the Company to Regulation 14A under the Securities
Exchange Act of 1934, as amended. At the annual meeting,
Proposals 1 and 2 were approved. The proposals below are
described in detail in the Companys definitive proxy statement
dated April 28, 2017 for the annual meeting.

The results are as follows:

Proposal 1

The following persons were nominated and elected directors:

Michael S.

Weiss

Laurence N.

Charney

William J.

Kennedy

Mark

Schoenebaum, MD

Yann

Echelard

Kenneth

Hoberman

Daniel

Hume

The shareholder voting for board members is summarized as
follows:

Director	Votes For	Votes Withheld	Abstentions	Broker Non-Votes
Michael S. Weiss	25,416,450	2,225,953	0	17,249,029
Laurence N. Charney	20,977,007	6,665,396	0	17,249,029
William J. Kennedy	21,489,066	6,153,337	0	17,249,029
Mark Schoenebaum, MD	12,631,181	15,011,222	0	17,249,029
Yann Echelard	27,358,300	284,103	0	17,249,029
Kenneth Hoberman	27,360,700	281,703	0	17,249,029
Daniel Hume	27,356,601	285,802	0	17,249,029

All seven directors will serve on the board of directors of the
Company (the Board) until the 2018 annual meeting.

Proposal 2

CohnReznick LLP was approved as the Companys independent
registered public accountant for the fiscal year ending December
31, 2017.

The votes cast were as follows:

Votes For		Votes Against		Abstentions		Broker Non-Votes
44,561,151		122,439		207,842		0

About TG Therapeutics, Inc. (NASDAQ:TGTX)
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.